New thyroid eye disease medicines are approved in the US. Can a Malaysian patient get them?

Three medicines are now approved in the United States for thyroid eye disease, and the headlines travel faster than the paperwork. The question I would ask next is the Malaysian one: can a patient here get them? This page answers it in three parts: what the US regulator approved and when, what the Malaysian medicine register showed on 6 November 2026, and what the official rules say about a medicine that is not registered. It is information, not a suggestion to look for any particular medicine.

Which thyroid eye disease medicines are approved in the US?

Three, each approved by the US Food and Drug Administration (FDA), the American medicines regulator. Teprotumumab has been approved since 2020, according to the FDA prescribing information, which lists 2020 as its initial US approval. Veligrotug was approved on 26 June 2026, as Ophthalmology Times reported. Satralizumab was approved on 15 October 2026, which Healio described as making it the third.

Teprotumumab and veligrotug are both infusions into a vein that block the IGF-1R receptor, a growth signal on the cells behind the eye. I explain what that does, and the hearing warning on the label, in infusion treatment for thyroid eye disease: what to ask. Satralizumab works differently. It blocks the interleukin-6 receptor, part of the inflammation signal, and it is an injection under the skin. Healio reports that patients or caregivers can give it at home after training from a healthcare provider.

The brand names are Tepezza (teprotumumab), Lumvoa (veligrotug) and Enspryng (satralizumab). They are given only because they are the names on boxes and in search results. The generic name, the name of the active ingredient, is the one that stays the same everywhere.

What did the trials behind the newest approval show?

They gave two different answers. The approval rests on two phase 3 trials, SatraGO-1 and SatraGO-2, which together enrolled 258 patients in 19 countries, according to Ophthalmology Times. SatraGO-2 met its main goal: a proptosis response, meaning the eye moving back, in 52.9% of those on satralizumab against 23.4% on placebo, and an improvement in double vision in 60.7% against 25.8%. SatraGO-1 missed its pre-specified main goal at week 24, both outlets report.

Both results matter, and I would not read the approval as saying that every trial succeeded. A regulator can approve on the weight of the evidence it was shown. The figures for the first trial, and the way the two trials compare, are in thyroid eye disease treatment beyond the infusion. One clinician quoted by Ophthalmology Times said it is still unclear how patients using the injection at home should be monitored, which is a fair reminder that a convenient route of giving a medicine does not remove the need for follow-up.

The word "first" appears often in this news. Where I use it on this page, it belongs to the FDA, the makers or the news outlets that wrote it, and it describes order of approval, not quality. No trial has compared these medicines with one another, so nobody can say from this evidence which is stronger.

Are these medicines registered in Malaysia?

The register showed different things for each, so the answer is not one word. Registration in Malaysia is done by the National Pharmaceutical Regulatory Agency (NPRA) of the Ministry of Health, and its public product search is called QUEST3+. A search of it on 6 November 2026 gave these results.

• Teprotumumab: searching the active ingredient teprotumumab, and separately the name Tepezza, returned one product, Tepezza 500 mg powder for infusion, registration number MAL26066010ACZ, held by Amgen Biopharmaceuticals Malaysia Sdn Bhd.
• Veligrotug: searching the active ingredient veligrotug, and separately the name Lumvoa, returned no results. It was not found on the register when checked on 6 November 2026.
• Satralizumab: searching the active ingredient returned one product, Enspryng 120 mg in a pre-filled syringe, registration number MAL22046009ACRZ, held by Roche (Malaysia) Sdn Bhd.

The register itself says that a result applies only to the date and time of the search and that a product's status can change with regulatory updates. So these lines are a snapshot, and I would treat them as one. If you want a current answer, run the search yourself or ask the pharmacy of the hospital that looks after you.

What does being on the register actually tell you?

Less than people hope. A listing means a product has been registered under that name by that company. It does not tell you which conditions the registration covers, whether the medicine is in stock, or whether a hospital or clinic you can reach stocks it. In the results above, the list view showed only the product, its number and its holder. When the register was checked on 6 November 2026, the detail panel for the Tepezza entry did not load, so its approved uses were not shown.

That matters most for satralizumab. Healio notes that the same drug was already approved in the US for a rare nerve condition, neuromyelitis optica spectrum disorder, before the thyroid eye disease approval on 15 October 2026. A medicine can be registered for one condition in one country and approved for another condition elsewhere, because each regulator reviews each use separately. The Enspryng entry on the Malaysian register therefore does not, on its own, show whether thyroid eye disease is among its registered uses here. This page makes no claim either way.

For Tepezza, the register page that loaded did not state the approved uses. The summary is this: a teprotumumab product is listed, a satralizumab product is listed with its uses unconfirmed, and veligrotug was not found.

What if a medicine is not registered, or not registered for this use?

Only the official routes count, and this page goes no further than the rules say. On 2 November 2026 the Ministry of Health told Parliament that it has a special drug approval mechanism through which patients who need a treatment can apply for approval, as The Star reported. That answer was given about weight-loss medicines. No official statement was found on whether, or how, the mechanism applies to thyroid eye disease medicines, so this page cannot say that it does.

On bringing a medicine in yourself, the Ministry's Pharmacy Enforcement FAQ says that, whether for personal use or for business, only registered products are imported, through a licence holder. No page was found that gives a personal allowance for an unregistered thyroid eye disease medicine, and none should be assumed to exist. Ordering a prescription medicine online from an overseas seller, or accepting a vial of unknown origin, is exactly the situation in which the product, its storage and its dose cannot be checked. The warning on my beyond-the-infusion page applies here too: discuss any unregistered product with your specialist before you consider it.

Medicines that need an infusion or monitoring are also given by trained staff for a reason. The label for teprotumumab asks for blood sugar and hearing to be assessed before, during and after treatment. A route that skips the people who do those checks removes a protection the label asks for.

What should I do now, and what should I ask?

Start with the doctors, not with the medicine. Thyroid eye disease is looked after by an endocrinologist for the thyroid and an eye surgeon with orbital training for the eyes, and who treats thyroid eye disease in Malaysia and where to go sets out the referral route. Whether any of these three medicines is suitable depends on whether the disease is active or settled, how severe it is, what else you have, and what is registered and supplied where you are treated. Only the treating team can weigh that, and nothing on this page is a recommendation to seek any of them.

These are the questions I would want answered before any decision:

• Is this medicine registered in Malaysia, and for thyroid eye disease specifically?
• If it is not registered, is there an official route for it, and who files the application?
• Is my disease active, and does the evidence cover my kind of disease?
• What checks, such as blood sugar and hearing, come before and during treatment?
• What is the plan if it does not work, and is surgery a better step?

The established treatments have not gone away. The European guideline still puts intravenous steroid with mycophenolate first for active moderate-to-severe disease, as I describe in thyroid eye disease and steroids, and stopping smoking helps whatever else is chosen. Sight-threatening disease, with blurred or dimming vision, is an emergency whichever medicine is available. Thyroid eye disease is one of several reasons eyes can change, and I place it among the others in what actually makes eyes look tired. The wider set is under orbit and thyroid eye disease.